Oct 6 (Reuters) - Insys Therapeutics Inc : :Insys Therapeutics addresses New Jersey complaint.Insys Therapeutics inc - company is under new management and has replaced 90 percent of original sales force and commercial organization.Insys Therapeutics says it continues to work with relevant authorities to resolve issues related to inappropriate actions taken by some of co's former employees.Accordingly, co has taken "a series of major actions to prevent mistakes of past from happening in future".
Oct 2 (Reuters) - CytRx Corp :CytRx Corp provides business update and highlights future plans.CytRx Corp - hopes to nominate next Linker Activated Drug Release discovery platform candidate for clinical development by end of 2017.CytRx Corp - CytRx ended Q2 of 2017 with $55 million in cash.CytRx Corp - restructured and paid down $10 million of its existing debt during Q3.
Sept 29 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL.VIKING THERAPEUTICS INC - ANNOUNCED IT HAS ENTERED INTO A $15.0 MILLION COMMON STOCK PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL FUND LLC.VIKING THERAPEUTICS INC - CONTINUE TO ANTICIPATE TOP LINE RESULTS FROM PHASE 2 TRIAL OF VK5211 IN HIP FRACTURE IN Q4 OF 2017.VIKING THERAPEUTICS - CO WILL HAVE RIGHT AND SOLE DISCRETION TO SELL TO LPC UP TO $15 MILLION IN SHARES OF COMMON STOCK OVER 30-MONTH PERIOD CONTINGENT.VIKING THERAPEUTICS - UNDER SEPARATE PURCHASE AGREEMENT, LINCOLN PARK CAPITAL FUND AGREED TO BUY $1.25 MILLION OF CO'S STOCK AT $1.78 PER SHARE.VIKING THERAPEUTICS - UNDER TERMS OF COMMON STOCK PURCHASE AGREEMENT, CO TO CONTROL TIMING, AMOUNT OF ANY FUTURE SALE OF SHARES OF COMMON STOCK TO LPC.
Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.
Sept 26 (Reuters) - Gtx Inc :GTx announces $48.5 million private placement.GTx - entered into agreement for sale of its common stock & warrants to purchase common stock in private placement with gross proceeds of $48.5 million.GTx -under terms of agreement, at close of placement, co will issue, sell 5.5 million shares to purchase up to 3.3 million additional shares of common stock.GTx Inc - co to purchase up to 3.3 million additional shares of common stock at a per unit purchase price of $8.845.
Sept 26 (Reuters) - EPS Holdings Inc <4282.T>:Says co's unit EP-SOGO Co., Ltd plans to fully acquire a Sapporo-based firm EXAM Co.,Ltd on Oct. 2.Says EXAM is mainly engaged in site management organization (SMO) business .Says acquisition price is undisclosed .
Sept 18 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc announces proposed public offering of common stock.Aldeyra Therapeutics - To offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.Aldeyra Therapeutics Inc says net proceeds to be used for continued development of Aldeyra's lead compound ADX-102 and other product candidates.
Sept 18 (Reuters) - Guangzhou Boji Medical & Biotechnological Co Ltd <300404.SZ>:Says its shares to resume trade on Sept 19 after halting asset restructuring plan.
Sept 14 (Reuters) - Achieve Life Sciences Inc :Achieve announces share purchase agreement with Lincoln Park Capital Fund LLC.Achieve Life Sciences - Entered share purchase agreement with Lincoln Park Capital Fund pursuant to which achieve may sell up to $11.0 million of shares.Achieve Life Sciences - Intends to use net proceeds it receives from offering to advance clinical development of Cytisine, among others.
Sept 13 (Reuters) - Epizyme Inc :Epizyme announces proposed public offering of common stock.Epizyme Inc says intends to offer and sell $120 million of shares of its common stock in an underwritten public offering.Epizyme-Will use net proceeds from this offering,existing cash, cash equivalents,marketable securities,to fund development costs of tazemetostat outside Japan.